Niki BioSolutions, Inc. — Form 8-K/A
Filed August 21, 2026 · analyzed by the 8-K Agent
8-K/A
— Neutral
significance 72/100
What the filing says
On July 20, 2026, Aptorum Group Limited completed its merger with DiamiR Biosciences Corp., acquiring the molecular diagnostics company for an estimated $17.5M (1,979,216 shares of Niki Common Stock valued at $8.83/share). DiamiR's convertible notes totaling ~$1.3M converted to 409,925 shares. Aptorum domesticated to Delaware, renamed itself Niki BioSolutions, Inc., and now trades on Nasdaq under ticker NIKI. Pro forma intangible assets assigned include $8.2M in patents, $6.8M in IPR&D, and $1.6M in trademark.
Why this rating
Material acquisition—DiamiR valued at ~$17.5M, 94% of Niki's $18.7M pre-deal assets. Transformational structurally (name change, public listing, reverse split), but pro forma shows combined entity highly unprofitable ($2M+ loss in 6mo 2026), going-concern issues, goodwill $1.1M (15% of purchase price), no revenue synergies quantified. Significant capital event but financial health unresolved.
See more from August 21, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.